sub:assertion {
  <http://purl.obolibrary.org/obo/MONDO_0100081> a biolink:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/MONDO_0100081> ;
    rdf:predicate biolink:treats ;
    rdf:subject <https://identifiers.org/DRUGBANK:DB01142> ;
    a rdf:Statement ;
    rdfs:label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." ;
    biolink:has_population_context sub:context ;
    biolink:provided_by <https://w3id.org/um/NeuroDKG> ;
    biolink:publications <https://pubmed.ncbi.nlm.nih.gov/31622593> ;
    biolink:relation <https://w3id.org/um/neurodkg/OffLabelIndication> .
  sub:context a biolink:Cohort ;
    rdfs:label "Adults" .
  <https://identifiers.org/DRUGBANK:DB01142> a biolink:Drug .
}